Pharmacist's Verdict
Vuity is a novel, prescription-only eye drop that effectively but temporarily improves age-related blurry near vision for some people, offering a daily alternative to reading glasses, though it comes with notable side effects and a high price tag.
Ingredient Analysis
Pilocarpine Hydrochloride 1.25%
Pros & Cons
Pros
- The first and only FDA-approved eye drop to treat age-related blurry near vision (presbyopia).
- Provides a non-surgical, glasses-free option for improving near and intermediate vision.
- Works relatively quickly, with noticeable improvement in as little as 15 minutes.
- The effects last for up to 6 hours, covering a significant part of a workday.
Cons
- Requires a doctor's prescription; it is not available over-the-counter.
- Very expensive and often not covered by insurance plans.
- Common side effects include headache, eye redness, and eye irritation.
- Can make it difficult to see in dim light, so caution is needed when driving at night.
- Carries a rare but serious risk of retinal detachment, especially for nearsighted individuals.
Safety Information
Potential Side Effects
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in labeling: Hypersensitivity [see Contraindications ( 4 )] Most common adverse reactions (>5%) are headache, conjunctival hyperemia, and eye irritation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. VUITY dosed once daily was evaluated in 375 participants with presbyopia in two randomized, double-masked, vehicle-contr…
Is Vuity safe for you?
See pregnancy, interactions, and common concerns answered in our pharmacist safety FAQ.
Read safety review →References
- 1.FDA Drug Label — VUITY
FDA DailyMed: VUITY · FDA
- 2.EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies.
Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al., Annals of the rheumatic diseases, 2020 · PubMed
- 3.Interventions for the Prevention of Oral Mucositis in Patients Receiving Cancer Treatment: Evidence from Randomised Controlled Trials.
Colella G, Boschetti CE, Vitagliano R, et al., Current oncology (Toronto, Ont.), 2023 · PubMed
- 4.Sjögren syndrome induced by anti PDL-1 treatment for TNBC: case report and review of literature.
Pellegrino C, D'Antonio C, Ierinò D, et al., Frontiers in immunology, 2024 · PubMed
- 5.Intracellular Peptides in Cell Biology and Pharmacology.
de Araujo CB, Heimann AS, Remer RA, et al., Biomolecules, 2019 · PubMed
- 6.Treatment of xerostomia and hyposalivation in the elderly: A systematic review.
Gil-Montoya JA, Silvestre FJ, Barrios R, et al., Medicina oral, patologia oral y cirugia bucal, 2016 · PubMed